REGISTER
Ocumension’s Dexamethasone Suspension Approved in China
On 1 July 2026, the NMPA approved Ocumension's dexamethasone ophthalmic suspension (OT-502) for treating post-cataract surgery inflammation. OT-502 is a biodegradable, single-injection sustained-release anti-inflammatory agent that releases dexamethasone for 21–22 days. It reduces postoperative eye drop use, improving patient compliance and simplifying post-surgical care.

On 1 July, the official website of the National Medical Products Administration (NMPA) showed that Ocumension’s dexamethasone ophthalmic suspension injection (OT-502) had been approved for marketing, indicated for the treatment of inflammation following cataract surgery.

OT-502 is a novel, biodegradable, single‑injection sustained‑release anti‑inflammatory agent that releases the active ingredient dexamethasone immediately after injection to exert its anti‑inflammatory effects, with sustained release lasting 21–22 days. The drug is designed to provide ophthalmologists with a single‑injection sustained‑release corticosteroid option at the end of surgery, which can significantly reduce patients’ need for postoperative eye drops, thereby improving patient compliance and streamlining the postoperative inflammation management process. In addition, the drug effectively simplifies the postoperative care routine for ophthalmic patients, offering more options for postoperative inflammation control.

In February 2018, the product was approved in the United States under the brand name Dexycu for the treatment of postoperative inflammation. In January 2020, Ocumension licensed OT-502 from EyePoint Pharmaceuticals, obtaining exclusive rights for development and commercialisation in China.

In April 2024, OT-502 completed its Phase III clinical trial in China. The results showed that on Day 8, the proportion of subjects with an anterior chamber cell grade of 0 was significantly higher than in the placebo group, demonstrating that the drug is safe and effective in controlling inflammation after cataract surgery.

0
0
Loading